Home/Filings/4/0001562180-20-000119
4//SEC Filing

DAVIS JOHN C. JR 4

Accession 0001562180-20-000119

CIK 0001690585other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 4:01 PM ET

Size

9.1 KB

Accession

0001562180-20-000119

Insider Transaction Report

Form 4
Period: 2020-01-02
DAVIS JOHN C. JR
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Stock Option (Right to Buy)

    2020-01-0211,294224,831 total
    Exercise: $9.49Exp: 2028-04-25Common Stock (11,294 underlying)
  • Sale

    Common Stock

    2020-01-02$15.04/sh11,294$169,8178,304 total
  • Exercise/Conversion

    Common Stock

    2020-01-02$9.49/sh+11,294$107,18019,598 total
Footnotes (3)
  • [F1]This trade is pursuant to an active 10b5-1 plan.
  • [F2]This transaction was executed in multiple trades at prices ranging from $15.00 to $15.09. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the staff of the U.S. Securities and Exchange Commission, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]25% vested on February 16, 2019 with the remaining 75% vesting in 12 equal quarterly installments thereafter.

Issuer

Magenta Therapeutics, Inc.

CIK 0001690585

Entity typeother

Related Parties

1
  • filerCIK 0001741287

Filing Metadata

Form type
4
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 4:01 PM ET
Size
9.1 KB